Institutional members access full text with Ovid®

Share this article on:

Long-Term Course of Opioid Addiction

Hser, Yih-Ing PhD; Evans, Elizabeth MA; Grella, Christine PhD; Ling, Walter MD; Anglin, Douglas PhD

doi: 10.1097/HRP.0000000000000052
Reviews

Opioid addiction is associated with excess mortality, morbidities, and other adverse conditions. Guided by a life-course framework, we review the literature on the long-term course of opioid addiction in terms of use trajectories, transitions, and turning points, as well as other factors that facilitate recovery from addiction. Most long-term follow-up studies are based on heroin addicts recruited from treatment settings (mostly methadone maintenance treatment), many of whom are referred by the criminal justice system. Cumulative evidence indicates that opioid addiction is a chronic disorder with frequent relapses. Longer treatment retention is associated with a greater likelihood of abstinence, whereas incarceration is negatively related to subsequent abstinence. Over the long term, the mortality rate of opioid addicts (overdose being the most common cause) is about 6 to 20 times greater than that of the general population; among those who remain alive, the prevalence of stable abstinence from opioid use is low (less than 30% after 10–30 years of observation), and many continue to use alcohol and other drugs after ceasing to use opioids. Histories of sexual or physical abuse and comorbid mental disorders are associated with the persistence of opioid use, whereas family and social support, as well as employment, facilitates recovery. Maintaining opioid abstinence for at least five years substantially increases the likelihood of future stable abstinence. Recent advances in pharmacological treatment options (buprenorphine and naltrexone) include depot formulations offering longer duration of medication; their impact on the long-term course of opioid addiction remains to be assessed.

From the University of California, Los Angeles.

Supported by National Institute on Drug Abuse grant nos. P30DA016383 (Dr. Hser) and U10DA13045 (Drs. Hser and Ling).

Original manuscript received 11 March 2014, accepted for publication subject to revision 25 April 2014; revised manuscript received 23 May 2014.

Correspondence: Yih-Ing Hser, PhD, 11075 Santa Monica Blvd., Suite 200, Los Angeles, CA 90025. Email: yhser@ucla.edu

© 2015 President and Fellows of Harvard College
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website